Bridget Hoyt

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical activity.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

The number of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.

The FDA approved penpulimab-kcqx combination and monotherapy for non-keratinizing nasopharyngeal carcinoma.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options.

The accelerated approval for nivolumab monotherapy in unresectable/metastatic MSI-H/dMMR CRC has also been converted to regular approval.

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

The FDA approved treatments in various gastrointestinal and genitourinary cancers in March.

Rates of pay, bonus pay, and changes to funding for continuing education were not significantly linked with burnout rates.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

Indications for 177Lu-PSMA-617 now include taxane-based chemotherapy naive adults with PSMA+ mCRPC.

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

Seth Eisenberg, ASN, RN, OCN, BMTCN, explained his research on a toilet cover for oncology nurses to potentially reduce exposure to infectious pathogens and hazardous drugs.

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected metastasis or suspected recurrence.